Shattuck Labs Inc STTK
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-09 |
| Shares Out. | 90,370,000 |
| Website | shattucklabs.com/ ↗ |
| Phone | 15129004690 |
| Employees | 40 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$15.2M |
| Free Cash Flow | -$41.2M |
| Total Assets | $220.7M |
| Total Liabilities | $9.5M |
| Equity | $211.1M |
About Shattuck Labs Inc
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Shattuck Labs Inc is a publicly traded company under the ticker symbol STTK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-09-01)